We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+0.71%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$341M
Cap. Flow
+$311M
Cap. Flow %
24.02%
Top 10 Hldgs %
81.93%
Holding
27
New
4
Increased
19
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$33.1M
2
VRDN icon
Viridian Therapeutics
VRDN
+$22.4M
3
CLDX icon
Celldex Therapeutics
CLDX
+$18.4M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$12.7M
5
COGT icon
Cogent Biosciences
COGT
+$5.77M

Top Sells

Rank Stock Value
1
LQDA icon
Liquidia Corp
LQDA
+$17.7M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 73.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$218M 16.83%
2,014,408
+14,408
+0.7% +$1.46M
VRTX icon
2
PUT
Vertex Pharmaceuticals
VRTX
$121B
$155M 11.93%
330,000
+230,000
+230% +$99.8M
CLDX icon
3
Celldex Therapeutics
CLDX
$2.77B
$125M 9.67%
3,388,967
+488,967
+17% +$18.4M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.84B
$117M 9.06%
5,722,057
+62,057
+1% +$1.3M
SPY icon
5
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$109M 8.42%
+200,000
New +$105M
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$79.5M 6.14%
7,082,562
+2,842,782
+67% +$33.1M
COGT icon
7
Cogent Biosciences
COGT
$6.79B
$78.1M 6.02%
9,260,385
+760,385
+9% +$5.77M
INSM icon
8
CALL
Insmed
INSM
$23.2B
$67M 5.17%
+1,000,000
New +$38.8M
PCVX icon
9
Vaxcyte
PCVX
$7.89B
$56.9M 4.39%
753,240
+8,240
+1% +$561K
VERA icon
10
Vera Therapeutics
VERA
$2.54B
$55.8M 4.31%
1,543,669
+16,882
+1% +$670K
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.37B
$54.5M 4.21%
8,826,710
+2,299,219
+35% +$12.7M
PTGX icon
12
Protagonist Therapeutics
PTGX
$8.75B
$27.7M 2.14%
800,000
-344,242
-30% -$10.1M
TSVT
13
DELISTED
2seventy bio
TSVT
$22.9M 1.77%
5,953,825
– –
VRDN icon
14
Viridian Therapeutics
VRDN
$2.13B
$22.8M 1.76%
1,750,000
+1,616,123
+1,207% +$22.4M
WVE icon
15
Wave Life Sciences
WVE
$1.12B
$19.8M 1.53%
3,975,521
+43,439
+1% +$248K
TVTX icon
16
Travere Therapeutics
TVTX
$5.33B
$16.6M 1.28%
2,021,659
+21,659
+1% +$146K
LQDA icon
17
Liquidia Corp
LQDA
$7.67B
$11M 0.85%
916,574
-1,331,750
-59% -$17.7M
IRWD icon
18
Ironwood Pharmaceuticals
IRWD
$611M
$10.7M 0.83%
1,641,891
+16,891
+1% +$119K
ALNY icon
19
PUT
Alnylam Pharmaceuticals
ALNY
$36.3B
$10.4M 0.81%
+43,000
New +$6.79M
TYRA icon
20
Tyra Biosciences
TYRA
$1.82B
$9.06M 0.7%
566,715
+51,525
+10% +$887K
AMRN
21
Amarin Corp
AMRN
$284M
$8.36M 0.65%
607,792
+6,644
+1% +$114K
BNR
22
Burning Rock Biotech
BNR
$94.4M
$6.28M 0.48%
974,668
+10,577
+1% +$80.5K
STRO icon
23
Sutro Biopharma
STRO
$379M
$5.93M 0.46%
202,368
+2,195
+1% +$86.8K
SLRN
24
DELISTED
ACELYRIN
SLRN
$3.67M 0.28%
831,310
+434,931
+110% +$2.04M
CRBU icon
25
Caribou Biosciences
CRBU
$156M
$2.7M 0.21%
1,646,702
+578,175
+54% +$1.85M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Kynam Capital Management held 27 positions worth $1.3B, up 36% from $955M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Kynam Capital Management deployed $311M of net new capital in Q2 2024, opening 4 new positions and adding to 19 existing holdings. Its largest new stake was CG Oncology: 53,911 shares worth $1.7M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Liquidia Corp, an estimated $17.7M trimmed.

  • Kynam Capital Management's largest Q2 2024 buy was CG Oncology: 53,911 shares worth $1.7M.
  • Kynam Capital Management added most to Dynavax Technologies in Q2 2024, an estimated $33.1M increase.
  • Kynam Capital Management's biggest Q2 2024 reduction was Liquidia Corp, cutting an estimated $17.7M.
  • Kynam Capital Management's ten largest holdings make up 82% of its $1.3B portfolio in Q2 2024.
  • Kynam Capital Management opened 4 new positions and closed 1 in Q2 2024.
  • Kynam Capital Management's portfolio value rose 36% quarter-over-quarter to $1.3B.

Based on Kynam Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.